In an initial study, with a small sample size of controls and AD patients (n = 35), we showed preliminary results that MTBR-tau was present in human CSF and that a specific MTBR-tau species containing residue 243 (MTBR-tau243) was strongly associated with tau-PET and disease progression33. This evidence concerns the gene MAPT and Alzheimer disease.